Skip to main content
Clinical Trials/CTRI/2018/05/013790
CTRI/2018/05/013790
Completed
Phase 4

Prospective, multi-centre, clinical study to evaluate theefficacy, safety and pharmacokinetics of HemoRel-A® in Hemophilia A patients

Dr Savita Rangarajan0 sites44 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Health Condition 1: null- Hemophilia A
Sponsor
Dr Savita Rangarajan
Enrollment
44
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
March 30, 2020
Last Updated
4 years ago
Study Type
Pms

Investigators

Sponsor
Dr Savita Rangarajan

Eligibility Criteria

Inclusion Criteria

  • 1\.Male subjects aged between 18 to 65 years (both inclusive.
  • 2\.Subjects with severe hemophilia A (documented factor VIII levels lesser than 1 percent) who are
  • receiving on\-demand treatment.
  • 3\.History of greater than 12 bleeding events in the past 12 months.
  • 4\. Number of exposure days before inclusion greater than 50 ED.
  • 5\.Immunocompetent with CD4 lymphocytes greater than 200/μl.
  • 6\. HIV negative or having a viral load less than 200 particles/μl approx 400000 copies/ml.
  • 7\.Willing to provide written Informed Consent.
  • 8\.Able to adhere to study schedules and requirements.

Exclusion Criteria

  • 1\. Subjects with history of inhibitors to FVIII
  • 2\. Any other inherited or acquired bleeding disorder
  • 3\. Subjects with any major systemic illness, and/or had known hypersensitivity to
  • HemoRel\-A® or any of its component.
  • 4\. Subjects with abnormal laboratory parameters like:
  • ï?§ Serum creatinine greater than 1\.5 times of upper normal limit
  • ï?§ AST or ALT greater 3 times of upper normal limit
  • ï?§ Platelet count less than 100,000/μL
  • ï?§ Hemoglobin less than 10\.0 gm/dL
  • ï?§ Neutrophils less than 1\.5 X 10 raised to 3/μL

Outcomes

Primary Outcomes

Not specified

Similar Trials